ROME, ITALY — Using the factor Xa inhibitor edoxaban (Savaysa/Lixiana, Daiichi Sankyo) to anticoagulate patients about to undergo electrical cardioversion for their atrial fibrillation (AF) seems ...
Aside from patient factors, a number of factors may influence the immediate success of cardioversion, that is, a complete failure to cardiovert. These include electrode placement, shock polarity, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback